Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

Clarification on 2022/02/16 media reports. Provided by: Medigen Vaccine Biologics Corporation
1.Date of occurrence of the event:2022/02/16
2.Company name: Medigen Vaccine Biologics Corp.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):head office
4.Reciprocal shareholding ratios:N/A
5.Name of the reporting media:Economic Daily News 2022/02/16 C04
6.Content of the report:Charles Chen, the President of MVC (6547) said
yesterday (02/15), MVC is also conducting the immuno-bridging phase 3
clinical trial in EU. The result is also expected to be released in the
2nd quarter of 2022.
7.Cause of occurrence:
After consultation with European Medicines Agency (EMA) and considering
the difficulty of recruiting subjects due to high vaccine coverage rate in
EU, MVC will submit the clinical trial results conducted in non-EU country
to EMA for review. If there is a specific progress, it will be announced
in accordance with the regulations.
8.Countermeasures:None
9.Any other matters that need to be specified:
New drug development requires long process, vast investments and with no
guarantee in success which may pose investment risks. The investors are
advised to exercise caution and conduct thorough evaluation.

Disclaimer

Medigen Vaccine Biologics Corporation published this content on 16 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 February 2022 06:13:02 UTC.
https://m.marketscreener.com/quote/stock/MEDIGEN-VACCINE-BIOLOGICS-45428599/news/Medigen-Vaccine-Biologics-Clarification-on-2022-02-16-media-reports-39483846/